Abstract
The final analysis of KEYNOTE-177 provides further evidence to support the use of pembrolizumab in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, although there was no significant difference in overall survival compared with chemotherapy. Luis Diaz Jr and colleagues randomly assigned patients to receive intravenous pembrolizumab 200 mg every 3 weeks (n=153) or the investigator's choice of chemotherapy regimen (n=154).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
